Tim Coughlin, CPA, has been a member of the board of directors of Travere Therapeutics, Inc. since 2015. Mr. Coughlin is the former CFO of Neurocrine Biosciences having served there from 2002 to 2018. Mr. Coughlin has developed expertise in corporate accounting, finance, and operations management of companies ranging in size from start-ups through Fortune 500. Prior to Neurocrine, he served as vice president of financial services at CHI, a nationwide integrated healthcare delivery system. From 1989 to 1999, Mr. Coughlin served as a senior manager in the health sciences practice of Ernst & Young, and its predecessors. Mr. Coughlin currently serves on the board of directors of aTyr Pharma, Inc., a biopharmacuetical company focused on immunotherapies for cancer and immune disorders, and of Fate Therapeutics, a clinical-stage biopharmaceutical company engaged in the discovery and development of pharmacologic modulators of adult stem cells to treat severe, life-threatening diseases. Mr. Coughlin holds a bachelor’s in accounting from Temple University and a master’s in international business from San Diego State University.